Rare disease by definition implies the patient numbers are very small, and therefore the return on investment has historically been challenging. Whilst advocacy groups have always been active in drawing attention to the plight of rare disease patients, a number of scientific and technology advances are changing the economics of advances in rare disease research.
In addition commercial organisations now appear more driven to make social investments that offer even more hope for those suffering from rare disease. In this chaitime chaired by Prashant shah, we explore the latest science, the economics and the role of patients in the fight against rare disease.
Michael is a VP of Rare Disease research at Pfizer and is a scientifically focused drug discovery and early clinical development professional.
Nicola is the editor in Chief of Rare Revolution Magazine which is a voice and a platform for patients groups, industry, professionals, clinical and healthcare providers and charities.
Tim Guilliams is the CEO of Healx and is passionate about using big data and artificial intelligence to accelerate treatments for rare diseases.
Prashant is a serial entrepreneur having begun a career with the Strategy group of at Accenture followed by co-founding two companies in the technology and life sciences sector.